Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

HomeRMH Score (Phase I Trials)
Pin your most used calculators here by clicking the star in the dropdown.

RMH Score (Phase I Trials)

Clinical Context & Background

The Royal Marsden Hospital (RMH) Score is a prognostic score used to stratify patients referred for Phase I clinical trials. It uses three objective markers (Albumin, LDH, Metastases) to predict survival, aiding in patient selection for early-phase studies.
Primary Source EvidenceArkenau HT, Barriuso J, Olmos D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol. 2009;27(16):2692-2696.
Formula Logic
Score 0-3 based on: Albumin < 35 g/L, LDH > ULN, and > 2 Metastatic Sites.

Reference Data

ScoreMedian Overall Survival
0 - 132.6 weeks (Good Prognosis)
2 - 316.7 weeks (Poor Prognosis)

Share This Calculator

Share:

Related Tools

ECOG Performance StatusBody Surface Area (BSA)Karnofsky Performance Status (KPS)

Evidence-based oncology decision support. Verify with clinical guidelines.